What is Drugs Made In America Acquisition II Corp.'s (DMII) StockRank?

MoatMap's StockRank for Drugs Made In America Acquisition II Corp. (DMII) is 4/100, with a Strong Sell signal. This is a composite score combining Quality (22), Value (22), and Momentum (26) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Drugs Made In America Acquisition II Corp. have an economic moat?

Drugs Made In America Acquisition II Corp. (DMII) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Drugs Made In America Acquisition II Corp. a buy, hold, or sell?

MoatMap's current signal for Drugs Made In America Acquisition II Corp. (DMII) is Strong Sell, based on a StockRank of 4/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Drugs Made In America Acquisition II Corp. in?

Drugs Made In America Acquisition II Corp. (DMII) operates in the Financial Services sector, specifically the Shell Companies industry (United States).

DMII

Strong SellSinker

Drugs Made In America Acquisition II Corp. · Financial Services · United States · $646M · Avg Vol: $604K/d

Sinker: Weak, expensive and falling. Nothing here to keep it afloat.

StockRank

Get insider-trade alerts

Quality

Value

Momentum

P/E (TTM)

35.1x

peers 12.6x

ROE

0.9%

peers 9.6%

D/E

—

peers 0.3x

Dividend %

—

trailing yield

Director trades · 180d

None →

Buybacks · 180d

None →

ABOUT DRUGS MADE IN AMERICA ACQUISITION II CORP.

Read

Drugs Made In America Acquisition II Corp. is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It does not have any operations and is currently seeking a target company, with a focus on pharmaceutical or biotechnology sectors within the United States. Its success depends on the management's ability to identify and merge with a promising enterprise.

FINANCIAL SUMMARY (USD)

Year	2024	2025	TTM
Revenue	—	0	—
EPS	—	0.16	0.29
Shares	63.7M	63.7M	63.7M
Debt	0.3M	—	0.5M
Equity	-0.1M	487.2M	—
Op CF	—	-1.0M	-1.3M
Inv CF	—	-500.0M	—
Fin CF	—	501.0M	—

Loading 1Y...

PRICE (1Y)+0.6%

SMA 50SMA 200

$10.17

RSI (14)

63.2

SCORE BREAKDOWN

Quality

ROIC

-0.3%12.4

ROE

0.9%25.0

GP/Assets

—N/A

Op. Margin

0.0%14.1

FCF/Assets

—N/A

Piotroski

215.7

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

0.34x14.6

Value

P/E (TTM)

35.1x10.5

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

-36.2x25.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

-14%29.0

SMA 50/200

—N/A

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$646M

P/E (Forward)

—

Gross Margin

—

SECTOR PEERS

Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of DMII are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DMII	Drugs Made In America Acquisition II Corp.(you)	$646M	4	Strong Sell
DBCA	D. Boral Acquisition I Corp.	$556M	4	Strong Sell
GHXI	Gores Holdings XI, Inc.	$539M	6	Strong Sell
MEVO	M Evo Global Acquisition Corp II	$501M	5	Strong Sell
GCGR	General Catalyst Global Resilience Merger Corp.	$515M	7	Strong Sell
CXII	Churchill Capital Corp XII	$602M	10	Strong Sell
IEAG	Infinite Eagle Acquisition Corp.	$445M	5	Strong Sell
PTOR	Praetorian Acquisition Corp.	$423M	5	Strong Sell
KRAQ	KRAKacquisition Corp.	$430M	6	Strong Sell
NWAX	New America Acquisition I Corp.	$507M	9	Strong Sell

Peer medians: ROE 9.6% · P/E 12.6x · Gross margin 100.0%

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

Drugs Made In America Acquisition II Corp. (DMII): Stock Score Summary

Drugs Made In America Acquisition II Corp. (DMII) has a MoatMap StockRank of 4/100 based on Quality (22/100), Value (22/100), and Momentum (26/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$10.17
Market Cap	$646M
P/E (TTM)	35.07
Price/Book	-36.19
Return on Equity	0.9%
Return on Invested Capital	-0.3%
Operating Margin	0.0%

Drugs Made In America Acquisition II Corp. operates in the Shell Companies industry, part of the Financial Services sector (United States).

Frequently Asked Questions

What is Drugs Made In America Acquisition II Corp.’s (DMII) StockRank?: MoatMap’s StockRank for Drugs Made In America Acquisition II Corp. (DMII) is 4/100, with a Strong Sell signal. It is a composite of Quality (22), Value (22), and Momentum (26) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Drugs Made In America Acquisition II Corp. have an economic moat?: Drugs Made In America Acquisition II Corp. (DMII) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Drugs Made In America Acquisition II Corp. a buy, hold, or sell?: MoatMap’s current signal for Drugs Made In America Acquisition II Corp. (DMII) is Strong Sell, based on a StockRank of 4/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Drugs Made In America Acquisition II Corp. in?: Drugs Made In America Acquisition II Corp. (DMII) operates in the Financial Services sector, specifically the Shell Companies industry (United States).